نتائج البحث - "Johanna C. Bendell"

1

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)

المصدر: Investigational new drugs, vol 39, iss 1
Invest New Drugs

مصطلحات موضوعية: 0301 basic medicine, Oncology, Organoplatinum Compounds, Metastatic pancreatic adenocarcinoma, Leucovorin, Phases of clinical research, Kaplan-Meier Estimate, Polyethylene Glycols, 0302 clinical medicine, FOLFOX, Antineoplastic Combined Chemotherapy Protocols, Pharmacology (medical), 6.2 Cellular and gene therapies, Cancer, education.field_of_study, Pharmacology and Pharmaceutical Sciences, Middle Aged, Progression-Free Survival, Interleukin-10, Tolerability, Pancreatic Ductal, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, IL-10, Fluorouracil, Pegilodecakin, Drug, Carcinoma, Pancreatic Ductal, medicine.drug, Adult, medicine.medical_specialty, Clinical Trials and Supportive Activities, Population, Phase 1, Article, Dose-Response Relationship, Pancreatic Cancer, 03 medical and health sciences, Rare Diseases, Clinical Research, Internal medicine, medicine, Humans, Oncology & Carcinogenesis, Pegylated IL-10, Adverse effect, education, Response Evaluation Criteria in Solid Tumors, Neoplasm Staging, Aged, Pharmacology, Dose-Response Relationship, Drug, business.industry, Carcinoma, Evaluation of treatments and therapeutic interventions, digestive system diseases, Oxaliplatin, Pancreatic Neoplasms, Regimen, 030104 developmental biology, Tumor progression, Digestive Diseases, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d69d0ddd9f3551a8ca0a4d0daab7d846Test
https://doi.org/10.1007/s10637-020-01000-6Test

2

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

المؤلفون: Ilsung Chang, Johanna C. Bendell, Raymond D. Meng, Premal Patel, Sandra M. Sanabria-Bohórquez, Daniel C. Cho, Patricia LoRusso, Matthew Wongchenko, Geoffrey I. Shapiro, Iris T. Chan, Yibing Yan, Luna Musib

المصدر: Investigational New Drugs. 39:163-174

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b9452c83b98676f0b80dbf0103f07238Test
https://doi.org/10.1007/s10637-020-00975-6Test

3

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

المؤلفون: Xuejing Wang, Katherine M Bell-McGuinn, Jimmy Hwang, Johanna C. Bendell, Hans Christian Reinhardt, Daphne L. Farrington, Celine Pitou, Helge Bischoff, Robert M. Campbell, Thomas Zander, Scott M. Hynes, Philip W. Iversen, Michael Thomas

المصدر: Investigational New Drugs. 38:1145-1155

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Pyridines, Population, Antineoplastic Agents, Models, Biological, p38 Mitogen-Activated Protein Kinases, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pharmacology (medical), Lung cancer, Adverse effect, education, Protein Kinase Inhibitors, Aged, Pharmacology, education.field_of_study, business.industry, Imidazoles, Cancer, Common Terminology Criteria for Adverse Events, Middle Aged, medicine.disease, Treatment Outcome, 030104 developmental biology, Response Evaluation Criteria in Solid Tumors, Pyrazines, 030220 oncology & carcinogenesis, Checkpoint Kinase 1, Pyrazoles, Ralimetinib, Female, business, Febrile neutropenia

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e75a04ddc23ef75c870beb94be16d9dTest
https://doi.org/10.1007/s10637-019-00873-6Test

4

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

المؤلفون: Herbert Hurwitz, Vaibhav Sahai, Chris Verslype, Jason Clark, Johanna C. Bendell, Ashwin Reddy Sama, Eric Van Cutsem, Manuel Hidalgo, Edward W Greeno, Eileen M. O'Reilly, Chung Pin Li, Kenneth H. Yu, Christopher James Walker, Fitzroy Dawkins, Teresa Macarulla, Marcelo Garrido Salvo

المصدر: Investigational New Drugs. 36:683-695

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Ruxolitinib, Placebo, Disease-Free Survival, Article, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Pancreatic cancer, Antineoplastic Combined Chemotherapy Protocols, Nitriles, medicine, Clinical endpoint, Humans, Pharmacology (medical), Aged, Aged, 80 and over, Pharmacology, business.industry, Hazard ratio, Janus Kinase 1, Janus Kinase 2, Middle Aged, medicine.disease, Chemotherapy regimen, Pancreatic Neoplasms, Clinical trial, Pyrimidines, 030104 developmental biology, 030220 oncology & carcinogenesis, Disease Progression, Pyrazoles, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4efb9dd95fab56ab09c97a08030248fTest
https://doi.org/10.1007/s10637-018-0580-2Test

5

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers

المؤلفون: Erika Hamilton, Hani Gabra, Kathleen M. Moore, Jennifer R. Diamond, Mark Poole, D. Ross Camidge, Martin D. Forster, Michael S. Gordon, David M. Waterhouse, Barbara A. Goff, Carolyn D. Britten, Johanna C. Bendell

المصدر: Invest New Drugs

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Mitochondrial inhibitor, Cell, Uterine Cervical Neoplasms, Neutropenia, Article, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Stable Disease, Pharmacokinetics, Ovarian cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, ME-344, Pharmacology (medical), Oncology & Carcinogenesis, Aged, Ovarian Neoplasms, Pharmacology, Lung, Dose-Response Relationship, Drug, Small cell lung cancer, business.industry, Middle Aged, medicine.disease, Isoflavones, Mitochondria, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Toxicity, Female, 1115 Pharmacology And Pharmaceutical Sciences, Topotecan, Neoplasm Recurrence, Local, Topoisomerase I Inhibitors, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14dee4e7e022a14638395d5059e46ddfTest
https://doi.org/10.1007/s10637-017-0444-1Test

6

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

المؤلفون: Jean-Luc Van Laethem, Frederico Longo Muñoz, Thea Kalebic, Khaldoun Almhanna, Maria Alsina, Carolina Muriel Lopez, Antonio Cubillo Gracian, Hadi Danaee, Irfan Firdaus, Zhan Ye, Adedigbo Fasanmade, Johanna C. Bendell, Wells A. Messersmith, David Wright, Richard A. Hubner, Maria Luisa Limon Miron

المصدر: Investigational New Drugs. 35:235-241

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, Immunoconjugates, Esophageal Neoplasms, Receptors, Enterotoxin, Phases of clinical research, Antineoplastic Agents, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Neutropenia, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Stomach Neoplasms, Internal medicine, medicine, Humans, Pharmacology (medical), Gastrointestinal cancer, Aged, Aged, 80 and over, Pharmacology, business.industry, Guanylate cyclase 2C, Middle Aged, medicine.disease, Interim analysis, Tumor Burden, Surgery, Treatment Outcome, 030104 developmental biology, Oncology, Monomethyl auristatin E, chemistry, 030220 oncology & carcinogenesis, Female, Esophagogastric Junction, Neoplasm Recurrence, Local, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15e4a2ebe65fb4b73b1a74204841d4eaTest
https://doi.org/10.1007/s10637-017-0439-yTest

7

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

المؤلفون: Lee-Anne Stayner, Yuehui Wu, G. Del Conte, Johanna C. Bendell, Rajeshwar Singh, Philippe L. Bedard, Albiruni Ryan Abdul Razak, Cornfeld Mark J, R. Greenwood, Leanne Cartee, Cristiana Sessa, Angelica Fasolo, Juneko E. Grilley-Olson, H. A. Burris, Carrie B. Lee, J. R. Infante

المصدر: Invest New Drugs

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, MAP Kinase Kinase 1, Phases of clinical research, Pharmacology, 0302 clinical medicine, Neoplasms, Tissue Distribution, Pharmacology (medical), Phosphoinositide-3 Kinase Inhibitors, Trametinib, Sulfonamides, TOR Serine-Threonine Kinases, MEK inhibitor, Middle Aged, Prognosis, Rash, Pyridazines, Survival Rate, Tolerability, 030220 oncology & carcinogenesis, Quinolines, Drug Therapy, Combination, Female, medicine.symptom, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Pyridones, Pyrimidinones, Article, Young Adult, 03 medical and health sciences, Pharmacokinetics, Internal medicine, Biomarkers, Tumor, medicine, Humans, Dosing, Adverse effect, Protein Kinase Inhibitors, Aged, Neoplasm Staging, business.industry, 030104 developmental biology, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c534d7a980196bd8d32b6653fb8a0fc2Test
https://doi.org/10.1007/s10637-016-0377-0Test

8

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors

المؤلفون: Michael S. Gordon, Shirin Arastu-Kapur, Hansen L. Wong, Johanna C. Bendell, Jeffrey R. Infante, Howard A. Burris, Anthony W. Tolcher, David S. Mendelson, Heidi H. Gillenwater, Kyriakos P. Papadopoulos

المصدر: Investigational New Drugs. 34:216-224

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, Maximum Tolerated Dose, Nausea, Administration, Oral, Antineoplastic Agents, Pharmacology, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pharmacokinetics, Neoplasms, Internal medicine, medicine, Humans, Pharmacology (medical), Adverse effect, Aged, Neoplasm Staging, Aged, 80 and over, Dose-Response Relationship, Drug, business.industry, Middle Aged, medicine.disease, Carfilzomib, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, Pharmacodynamics, Vomiting, Proteasome inhibitor, Female, medicine.symptom, business, Oligopeptides, Proteasome Inhibitors, Hypophosphatemia, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5b434cde377daa673bea93ab1e8657bTest
https://doi.org/10.1007/s10637-016-0327-xTest

9

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

المؤلفون: Hirokazu Mizuguchi, Manish R. Patel, Johanna C. Bendell, Fabio Benedetti, C. Zergebel, Robert J. Mayer, Donghu Lin, Lee S. Rosen, Jonathan W. Goldman, Jeffrey R. Infante

المصدر: Cancer Chemotherapy and Pharmacology

مصطلحات موضوعية: Male, Oncology, Cancer Research, Pyrrolidines, Gastrointestinal Diseases, Colorectal cancer, Antimetabolite, Administration, Oral, Salvage therapy, Kaplan-Meier Estimate, Toxicology, Trifluridine, Recommended dose, Pharmacology (medical), Fatigue, Aged, 80 and over, Antitumor activity, Metastatic colorectal cancer, Middle Aged, TAS-102, Drug Combinations, Treatment Outcome, Adenocarcinoma, Female, Original Article, Erratum, Safety, Colorectal Neoplasms, Adult, Antimetabolites, Antineoplastic, medicine.medical_specialty, medicine.drug_class, Disease-Free Survival, Refractory, Internal medicine, medicine, Humans, In patient, Uracil, Aged, Febrile Neutropenia, Salvage Therapy, Pharmacology, Dose-Response Relationship, Drug, business.industry, medicine.disease, Surgery, Phase 1 study, business, Thymine, Febrile neutropenia

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b50744f48d8a6bb749d99c3d72bf8ee7Test
https://doi.org/10.1007/s00280-015-2850-4Test

10

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

المؤلفون: L Finney, Johanna C. Bendell, Jeffrey R. Infante, Kent C. Shih, Carla Kurkjian, Howard A. Burris, Todd M. Bauer, Cassie M. Lane, Suzanne F. Jones, F. Anthony Greco, D. S. Thompson

المصدر: Investigational New Drugs. 33:463-471

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::928aaf34cbc9fc1524feb8162c8de568Test
https://doi.org/10.1007/s10637-015-0218-6Test

تنقيح النتائج